A5003473518- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Radiomics and Machine Learning in Medical Imaging
- Cancer Mechanisms and Therapy
- Soft tissue tumors and treatment
- Lung Cancer Treatments and Mutations
- Cerebrovascular and Carotid Artery Diseases
- Health Systems, Economic Evaluations, Quality of Life
- AI in cancer detection
- Ubiquitin and proteasome pathways
- Cancer Research and Treatments
- Intracranial Aneurysms: Treatment and Complications
- Economic and Financial Impacts of Cancer
- Advances in Oncology and Radiotherapy
- Lung Cancer Diagnosis and Treatment
- Acute Ischemic Stroke Management
- Glioma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Moyamoya disease diagnosis and treatment
- Testicular diseases and treatments
- Brain Metastases and Treatment
- Sirtuins and Resveratrol in Medicine
Hospital Universitario Virgen del Rocío
2013-2024
Universidad de Sevilla
2016-2024
Centro de Investigación Biomédica en Red de Cáncer
2020-2024
Instituto de Biomedicina de Sevilla
2016-2024
Instituto de Salud Carlos III
2018-2024
Complejo Hospitalario Universitario de Toledo
2012-2023
Consejo Superior de Investigaciones Científicas
2017-2022
// Antonio Lucena-Cacace 1, 2 , Daniel Otero-Albiol Manuel P. Jiménez-García Javier Peinado-Serrano 1 and Amancio Carnero Instituto de Biomedicina Sevilla, IBIS, Hospital Universitario Virgen del Rocio, Universidad Consejo Superior Investigaciones Cientificas, Spain CIBER DE CANCER, Salud Carlos III, Madrid, Correspondence to: Carnero, email: acarnero-ibis@us.es Keywords: NAMPT, cancer initiating cell, gene signature, glioma, glioblastoma Received: June 22, 2017 Accepted: July 25, Published:...
Active therapeutic combinations, such as trabectedin and radiotherapy, offer potentially higher dimensional response in second-line treatment of advanced soft-tissue sarcomas. Dimensional can be relevant both for symptom relief survival.To assess the combined use radiotherapy treating patients with progressing metastatic sarcomas.Phase 1 this nonrandomized clinical trial followed classic 3 + design, planned at a fixed dose 30 Gy (3 Gy/d 10 days) infusion 1.3 mg/m2 starting dose, 1.5 level...
Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children young adults. Surgery radiation therapy the accepted treatments most sarcomas; however, patients with metastatic disease treated systemic chemotherapy. Many display marginal levels chemoresponsiveness, new treatment approaches needed. MAP17 is small non-glycosylated membrane protein overexpressed carcinomas. The could be used as prognostic marker to predict response bortezomib...
Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin radiotherapy showed activity a recently reported clinical trial this setting. This retrospective series aims to analyze our experience with the same regimen real-life We retrospectively reviewed treated concomitantly palliative intent. Growth-modulation index (GMI) was calculated as surrogate efficacy. Forty metastatic were analyzed....
// Eva M. Verdugo-Sivianes 1, 2 , Lola Navas Sonia Molina-Pinelo Irene Ferrer 2, 3 Alvaro Quintanal-Villalonga Javier Peinado 4 Jose Garcia-Heredia 5 Blanca Felipe-Abrio Sandra Muñoz-Galvan Juan J. Marin 6 Luis Montuenga 7 Paz-Ares and Amancio Carnero 1 Instituto de Biomedicina Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Universidad Sevilla, Consejo Superior Investigaciones Científicas, Spain CIBER Cáncer, Salud Carlos III, Pabellón 11, Planta 0, Madrid, H120-CNIO Lung Cancer...
Rectal cancer represents approximately 10% of cancers worldwide. Preoperative chemoradiotherapy increases complete pathologic response and local control, although it offers a poor advantage in survivorship sphincter saving compared with that radiotherapy alone. After preoperative chemoradiotherapy, 20% patients rectal achieve to the removed surgical specimen; this may be related better prognosis an improvement disease-free survival. However, biomarkers predict new targets are needed stratify...
Colorectal cancer (CRC) is the third most common worldwide. The standard treatment in locally advanced rectal preoperative radiation alone or combination with chemotherapy, followed by adjuvant chemotherapy. Rectal highly lethal, only 20% of patients showing a complete remission (by RECIST) after treatment, although they commonly show local systemic relapse likely due to its late detection and high chemotherapy resistance, among other reasons. Here, we explored role PAI1 (Serpin E1) through...
Background and objectives: Dimensional response is an unmet need in second lines of advanced soft tissue sarcomas (STS). Indeed, the three approved drugs, pazopanib, trabectedin, eribulin, achieved overall rate (ORR) less than 10%. This fact potentially hinders options for fast symptomatic relief or surgical rescue. The combination trabectedin plus low-dose radiation therapy (T-XRT) demonstrated a 60% phase I/II trial, while real-life data 32.5% ORR, probably due to more relaxed timing...
11514 Background: Myxoid liposarcoma (ML) exhibits especial sensitivity to trabectedin (T). In prospective series, T showed responses in 44% of patients (pts) with ML. ML is also sensitive radiation therapy (RT) and preclinical data suggested radiosensitizing properties T. Preoperative short-course concurrent low-dose RT was conducted a multicenter, European, phase I/II trial. We present here the from II part pts centralized diagnosis locally advanced, resectable Methods: Pts received 3...
Non-small-cell lung cancer (NSCLC) is the leading cause of death worldwide, generating an enormous economic and social impact that has not stopped growing in recent years. Cancer treatment for this neoplasm usually includes surgery, chemotherapy, molecular targeted treatments, ionizing radiation. The prognosis terms overall survival (OS) disparate therapeutic responses among patients can be explained, to a great extent, by existence widely heterogeneous profiles. main objective study was...
Transcervical carotid artery revascularization (TCAR) has demonstrated a low overall stroke rate in stenting (CAS). Furthermore, the use of double-layer micromesh stent is expected to reduce embolization and plaque prolapse. The combination TCAR double layer may lead improved results compared previously reported outcomes. objective this study present findings prospective including patients treated with Roadsaver TCAR.
11061 Background: Myxoid liposarcoma/round cell liposarcoma (ML) exhibits especial sensitivity to trabectedin (T). In prospective series, long-lasting T treatment showed responses in 44% of patients (pts) with ML. ML is also sensitive radiation therapy (RT) and preclinical data suggested radiosensitizing properties T. Preoperative short-course concurrent low-dose RT was conducted a multicenter, European, phase I/II trial. We present here from the I part pts centralized diagnosis locally...
11544 Background: Patients (pts) with advanced STS who require tumor shrinkage beyond first line, have very limited options since the approved drugs exhibit less than 10% of RECIST response. Trabectedin (T) had shown preclinical synergy radiotherapy (RT). Low-dose RT concurrent T was conducted in a phase I/II trial as proof-of-concept synergy. We present here data from I (pulmonary metastatic cohort) Methods: Pts received along (30 Gy) 10 fractions (3Gy/fr). Dose Levels for were: -1 (1.1...
Introduction In recent years, the molecular mechanisms involved in development of ovary tumours have been studied, although little is known about high resistance these to conventional therapies. We found that expression myosin phosphatase-targeting subunit 1 (MYPT1), which has related cancer progression, tumour samples versus normal tissues was reduced, as also overall survival patients. MYPT1 a regulator protein phosphatase (PP1C), play critical roles controlling phosphorylation states...